Gan & Lee Pharmaceuticals. (603087.SS)

48.77 +0.77 (+1.60%) At close: 03:00PM CST

Gan & Lee Pharmaceuticals.

No. 8, Nanfeng West 1st Street
Huoxian Town Tongzhou District
Beijing 101109
China
86 10 8059 3699
https://www.ganlee.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gan Zhongru	Founder & Chairman	N/A	N/A	1948
Mr. Kai Du	GM & Director	N/A	N/A	1977
Mr. Cheng Sun	CFO & Deputy GM	N/A	N/A	1979
Mr. Weiqiang Song	Deputy GM & Director	N/A	N/A	1982
Ms. Cheng Xing	Deputy General Manager	N/A	N/A	1991
Ms. Zifei Yuan	Deputy General Manager	N/A	N/A	1989
Ms. Rong Zou	Secretary	N/A	N/A	1983

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company's products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

Corporate Governance

Gan & Lee Pharmaceuticals.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.